Recombinant Human FZR1 Protein, N-His from ProteoGenix; catalogue ARO-P12236; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant proteins are synthetic proteins that are produced in a laboratory using genetic engineering techniques. These proteins have a wide range of applications in various fields, including medicine, biotechnology, and research. One such recombinant protein is the Recombinant Human FZR1 Protein, which has gained significant attention in the scientific community due to its unique structure and diverse functions.
The Recombinant Human FZR1 Protein is a 78 kDa protein that consists of 694 amino acids. It is a member of the F-box family of proteins, which play a crucial role in regulating the cell cycle and maintaining genomic stability. The FZR1 protein has a conserved F-box domain at the N-terminus and seven WD40 repeats at the C-terminus. These structural features allow the protein to interact with other proteins and form a complex, which is essential for its activity.
The FZR1 protein is a key regulator of the cell cycle, specifically the transition from the G2 phase to the M phase. It acts as a substrate recognition component of the anaphase-promoting complex/cyclosome (APC/C), which is responsible for the degradation of cell cycle regulators. The FZR1 protein recognizes and binds to specific proteins, such as cyclins and securins, and targets them for degradation by the APC/C. This process is crucial for maintaining the balance between cell proliferation and cell death, and any dysregulation can lead to various diseases, including cancer.
The Recombinant Human FZR1 Protein has numerous applications in both research and medicine. Its role in regulating the cell cycle makes it a valuable tool for studying cell division and its dysregulation in diseases such as cancer. The protein can be used to investigate the mechanisms of cell cycle control and identify potential targets for therapeutic interventions.
In the field of medicine, the FZR1 protein has been studied for its potential as a biomarker for cancer diagnosis and prognosis. Studies have shown that alterations in the expression of FZR1 can be detected in various types of cancer, making it a promising candidate for early detection and monitoring of the disease.
Furthermore, the FZR1 protein has also been investigated for its therapeutic potential. Research has shown that targeting FZR1 can inhibit the growth of cancer cells and sensitize them to chemotherapy. This highlights the potential of FZR1 as a target for cancer treatment.
The Recombinant Human FZR1 Protein is a crucial player in the regulation of the cell cycle and has a wide range of applications in research and medicine. Its unique structure and activity make it a valuable tool for studying cell division and its dysregulation in diseases such as cancer. Further research on this protein can lead to a better understanding of the cell cycle and potential treatments for cancer and other diseases.
ProteoGenix catalogue number ARO-P12236. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 38.25 kDa; Fragment: Ser172-Arg496; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
